PPARγ and its ligands: Therapeutic implications in cardiovascular disease

Clinical Science

Volumn 116, Issue 3, 2009, Pages 205-218

  Villacorta, Luis ^a   Schopfer, Francisco J ^b   Zhang, Jifeng ^a   Freeman, Bruce A ^b   Chen, Y Eugene ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Diabetes; Drug design; Fatty acid; Nitroalkenes; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

ALKENE DERIVATIVE; AMILORIDE; BISPHENOL A BIS(2 HYDROXYPROPYL) ETHER DIMETHACRYLATE; FATTY ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE TRANSPORTER 4; HALOFENATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; IRBESARTAN; LG 100641; LOOP DIURETIC AGENT; LOSARTAN; METAGLIDASEN; MYOSIN HEAVY CHAIN ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; PD 068235; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE; SULFONYLUREA; T 2384; TELMISARTAN; THIAZIDE DIURETIC AGENT; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNSATURATED FATTY ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; LIGAND;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TARGETING; FATTY LIVER; HEART INFARCTION; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOLYSIS; PERIPHERAL EDEMA; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; ANIMAL; DIABETIC ANGIOPATHY; DISEASE MODEL; DRUG DESIGN; DRUG POTENTIATION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; LIGANDS; MICE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 60549092887     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080195     Document Type: Review

References (138)

1. Abegunde, D. O., Mathers, C. D., Adam, T., Ortegon, M. and Strong, K. (2007) The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 370, 1929-1938
2. Fonseca, V. A. (2003) Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am. J. Cardiol. 92, 50J-60J
3. Mizuno, C. S., Chittiboyina, A. G., Kurtz, T. W., Pershadsingh, H. A. and Avery, M. A. (2008) Type 2 diabetes and oral antihyperglycemic drugs. Curr. Med. Chem. 15, 61-74
4. Donnelly, R. and Davis, K. R. (2000) Type 2 diabetes and atherosclerosis. Diabetes Obes. Metab. 2 (Suppl. 1), S21-S30
5. Gerstein, H. C., Miller, M. E., Byington, R. P. et al. (2008) Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559
6. Nathan, D. M., Buse, J. B., Davidson, M. B. et al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49, 1711-1721
7. Touyz, R. M. and Schiffrin, E. L. (2006) Peroxisome proliferator-activated receptors in vascular biology: molecular mechanisms and clinical implications. Vasc. Pharmacol. 45, 19-28
8. Yki-Jarvinen, H. (2004) Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118
9. Nissen, S. E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471
10. Lincoff, A. M., Wolski, K., Nicholls, S. J. and Nissen, S. E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, J. Am. Med. Assoc. 298, 1180-1188
11. Chen, Y. E., Fu, M., Zhang, J. et al. (2003) Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam. Horm. 66, 157-188
12. Hsueh, W. A., Jackson, S. and Law, R. E. (2001) Control of vascular cell proliferation and migration by PPAR-γ: a new approach to the macrovascular complications of diabetes. Diabetes Care 24, 392-397
13. Marx, N., Duez, H., Fruchart, J. C. and Staels, B. (2004) Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94, 1168-1178
14. Langenfeld, M. R., Forst, T., Hohberg, C. et al. (2005) Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 111, 2525-2531
15. Law, R. E., Goetze, S., Xi, X. P. et al. (2000) Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101, 1311-1318
16. Marx, N., Bourcier, T., Sukhova, G. K., Libby, P. and Plutzky, J. (1999) PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546-551
17. Marx, N., Schonbeck, U., Lazar, M. A., Libby, P. and Plutzky, J. (1998) Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83, 1097-1103
18. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998) The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82
19. Bruemmer, D., Yin, F., Liu, J. et al. (2003) Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. Circ. Res. 93, e38-e47
20. Collins, A. R., Meehan, W. P., Kintscher, U. et al. (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21, 365-371
21. Igarashi, M., Takeda, Y., Ishibashi, N. et al. (1997) Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm. Metab. Res. 29, 444-449
22. Yoshimoto, T., Naruse, M., Shizume, H. et al. (1999) Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145, 333-340
23. Joner, M., Farb, A., Cheng, Q. et al. (2007) Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-β and MCP-1. Arterioscler. Thromb. Vasc. Biol. 27, 182-189
24. Hong, G., Davis, B., Khatoon, N., Baker, S. F. and Brown, J. (2003) PPARγ-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNFα secretion is not mediated by PTEN regulation. Biochem. Biophys. Res. Commun. 303, 782-787
25. Jiang, C., Ting, A. T. and Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86
26. Sugawara, A., Takeuchi, K., Uruno, A. et al. (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-γ in vascular smooth muscle cells. Endocrinology 142, 3125-3134
27. Diep, Q. N., El Mabrouk, M., Cohn, J. S. et al. (2002) Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation 105, 2296-2302
28. Sorrentino, S. A., Bahlmann, F. H., Besler, C. et al. (2007) Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 116, 163-173
29. Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M. and Olefsky, J. (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188-1193
30. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. and Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953-12956
31. Barroso, I., Gurnell, M., Crowley, V. E. et al. (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883
32. Tsai, Y. S., Kim, H. J., Takahashi, N. et al. (2004) Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J. Clin. Invest. 114, 240-249
33. Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M. and Sigmund, C. D. (2004) PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43, 661-666
34. Walker, A. B., Chattington, P. D., Buckingham, R. E. and Williams, G. (1999) The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48, 1448-1453
35. Wu, L., Wang, R., De Champlain, J. and Wilson, T.W. (2004) Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats. Am. J. Hypertens. 17, 749-756
36. Hodroj, W., Legedz, L., Foudi, N. et al. (2007) Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler. Thromb. Vasc. Biol. 27, 525-531
37. Kamide, K., Rakugi, H., Nagai, M. et al. (2004) Insulin-mediated regulation of the endothelial renin - angiotensin system and vascular cell growth. J. Hypertens. 22, 121-127
38. Savoia, C., Touyz, R. M., Endemann, D. H. et al. (2006) Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 48, 271-277
39. Hoo, R. L., Chow, W. S., Yau, M. H. et al. (2007) Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler. Thromb. Vasc. Biol. 27, 2777-2782
40. Ohman, M. K., Shen, Y., Obimba, C. I. et al. (2008) Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 117, 798-805
41. Golledge, J., Mangan, S. and Clancy, P. (2007) Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas. Stroke 38, 1501-1508
42. Luo, Y., Yin, W., Signore, A. P. et al. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J. Neurochem. 97, 435-448
43. Tureyen, K., Kapadia, R., Bowen, K. K. et al. (2007) Peroxisome proliferator-activated receptor-γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101, 41-56
44. Zhang, J., Fu, M., Cui, T. et al. (2004) Selective disruption of PPARγ 2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 101, 10703-10708
45. Rosen, E. D., Kulkarni, R. N., Sarraf, P. et al. (2003) Targeted elimination of peroxisome proliferator-activated receptorγ in β-cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol. Cell. Biol. 23, 7222-7229
46. Medina-Gomez, G., Gray, S. L., Yetukuri, L. et al. (2007) PPARγ 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64
47. He, W., Barak, Y., Hevener, A. et al. (2003) Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100, 15712-15717
48. Hevener, A. L., He, W., Barak, Y. et al. (2003) Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9, 1491-1497
49. Norris, A. W., Chen, L., Fisher, S. J. et al. (2003) Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112, 608-618
50. Knouff, C. and Auwerx, J. (2004) Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25, 899-918
51. Matsusue, K., Haluzik, M., Lambert, G. et al. (2003) Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111, 737-747
52. Gavrilova, O., Haluzik, M., Matsusue, K. et al. (2003) Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276
53. Son, N. H., Park, T. S., Yamashita, H. et al. (2007) Cardiomyocyte expression of PPARγ leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791-2801
54. Duan, S. Z., Ivashchenko, C. Y., Russell, M. W., Milstone, D. S. and Mortensen, R. M. (2005) Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice. Circ. Res. 97, 372-379
55. Ding, G., Fu, M., Qin, Q. et al. (2007) Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc. Res. 76, 269-279
56. Caglayan, E., Stauber, B., Collins, A. R. et al. (2008) Differential roles of cardiomyocyte and macrophage PPARγ in cardiac fibrosis. Diabetes 57, 2470-2479
57. Sena, S., Rasmussen, I. R., Wende, A. R. et al. (2007) Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-γ agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148, 6047-6053
58. Hevener, A. L., Olefsky, J. M., Reichart, D. et al. (2007) Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 117, 1658-1669
59. Babaev, V. R., Yancey, P. G., Ryzhov, S. V. et al. (2005) Conditional knockout of macrophage PPARγ increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 1647-1653
60. Nicol, C. J., Adachi, M., Akiyama, T. E. and Gonzalez, F. J. (2005) PPARγ in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18, 549-556
61. Hansmann, G., de Jesus Perez, V. A., Alastalo, T. P. et al. (2008) An antiproliferative BMP-2/PPARγ/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 118, 1846-1857
62. Halabi, C. M., Beyer, A. M., de Lange, W. J. et al. (2008) Interference with PPARγ function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 7, 215-226
63. Beyer, A. M., Baumbach, G. L., Halabi, C. M. et al. (2008) Interference with PPARγ signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51, 867-871
64. Nesto, R. W., Bell, D., Bonow, R. O. et al. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108, 2941-2948
65. Guan, Y., Hao, C., Cha, D. R. et al. (2005) Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat. Med. 11, 861-866
66. Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J. and Yang, T. (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U.S.A. 102, 9406-9411
67. Hong, G., Lockhart, A., Davis, B. et al. (2003) PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells. FASEB J. 17, 1966-1968
68. Karalliedde, J., Buckingham, R., Starkie, M., Lorand, D., Stewart, M. and Viberti, G. (2006) Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J. Am. Soc. Nephrol. 17, 3482-3490
69. Emoto, M., Fukuda, N., Nakamori, Y. et al. (2006) Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. Diabetologia 49, 2217-2218
70. Sotiropoulos, K. B., Clermont, A., Yasuda, Y. et al. (2006) Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist's effects on edema and weight gain. FASEB J. 20, 1203-1205
71. Yoshioka, K., Wakino, S., Homma, K. et al. (2008) Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-γ ligands in ovariectomized obese rats. Obesity 16, 965-971
72. Pan, H. J., Reifsnyder, P., Vance, D. E., Xiao, Q. and Leiter, E. H. (2005) Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 54, 1854-1862
73. Pan, H. J., Lin, Y., Chen, Y. E., Vance, D. E. and Leiter, E. H. (2006) Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism. Vasc. Pharmacol. 45, 65-71
74. Kahn, S. E., Zinman, B., Lachin, J. M. et al. (2008) Rosiglitazone associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31, 845-851
75. hyp/hyp mice relocates haematopoiesis to the spleen. EMBO Rep. 5, 1007-1012
76. Akune, T., Ohba, S., Kamekura, S. et al. (2004) PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J. Clin. Invest. 113, 846-855
77. Wan, Y., Chong, L. W. and Evans, R. M. (2007) PPAR-γ regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503
78. Sakamoto, J., Kimura, H., Moriyama, S. et al. (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278, 704-711
79. Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J. and Peters, J. M. (2006) The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269-295
80. Goldberg, R. B., Kendall, D. M., Deeg, M. A. et al. (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28, 1547-1554
81. Guerre-Millo, M., Gervois, P., Raspe, E. et al. (2000) Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638-16642
82. Barter, P. J. and Rye, K. A. (2008) Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler. Thromb. Vasc. Biol. 28, 39-46
83. Nissen, S. E., Wolski, K. and Topol, E. J. (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA, J. Am. Med. Assoc. 294, 2581-2586
84. Tenenbaum, A., Motro, M., Fisman, E. Z. et al. (2004) Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109, 2197-2202
85. Rubenstrunk, A., Hanf, R., Hum, D. W., Fruchart, J. C. and Staels, B. (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771, 1065-1081
86. Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N. and Noy, N. (2007) Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723-733
87. Schupp, M., Curtin, J. C., Kim, R. J., Billin, A. N. and Lazar, M. A. (2007) A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-γ activity. Mol. Pharmacol. 71, 1251-1257
88. Allen, T., Zhang, F., Moodie, S. A. et al. (2006) Halofenate is a selective peroxisome proliferator-activated receptor γ modulator with antidiabetic activity. Diabetes 55, 2523-2533
89. Rocchi, S., Picard, F., Vamecq, J. et al. (2001) A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell 8, 737-747
90. Berger, J. P., Petro, A. E., Macnaul, K. L. et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein-γ selective modulator. Mol. Endocrinol. 17, 662-676
91. Zhang, F., Lavan, B. E. and Gregoire, F. M. (2007) Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007, 32696
92. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. and Kliewer, S. A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410
93. Acton, III, J. J., Black, R. M., Jones, A. B. et al. (2005) Benzoyl 2-methyl indoles as selective PPARγ modulators. Bioorg. Med. Chem. Lett. 15, 357-362
94. Dropinski, J. F., Akiyama, T., Einstein, M. et al. (2005) Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARγ partial agonists. Bioorg. Med. Chem. Lett. 15, 5035-5038
95. Chang, C. H., McNamara, L. A., Wu, M. S. et al. (2008) A novel selective peroxisome proliferator-activator receptor-γ modulator-SPPARγ M5 improves insulin sensitivity with diminished adverse cardiovascular effects. Eur. J. Pharmacol. 584, 192-201
96. Minoura, H., Takeshita, S., Ita, M. et al. (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur. J. Pharmacol. 494, 273-281
97. Shinkai, H., Onogi, S., Tanaka, M. et al. (1998) Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem. 41, 1927-1933
98. Blanc-Delmas, E., Lebegue, N., Wallez, V. et al. (2006) Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARγ agonists. Bioorg. Med. Chem. Lett. 14, 7377-7391
99. Rybczynski, P. J., Zeck, R. E., Combs, D. W. et al. (2003) Benzoxazinones as PPARγ agonists. part 1: SAR of three aromatic regions. Bioorg. Med. Chem. Lett. 13, 2359-2362
100. Chittiboyina, A. G., Venkatraman, M. S., Mizuno, C. S. et al. (2006) Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARγ agonists. J. Med. Chem. 49, 4072-4084
101. Burgermeister, E., Schnoebelen, A., Flament, A. et al. (2006) A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ) recruits PPARγ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol. 20, 809-830
102. Miles, P. D., Barak, Y., He, W., Evans, R. M. and Olefsky, J. M. (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J. Clin. Invest. 105, 287-292
103. Rieusset, J., Touri, F., Michalik, L. et al. (2002) A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol. 16, 2628-2644
104. Li, Y., Wang, Z., Furukawa, N. et al. (2008) T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor-γ binding properties. J. Biol. Chem. 283, 9168-9176
105. Javeshghani, D., Sairam, M. R., Neves, M. F., Schiffrin, E. L. and Touyz, R. M. (2006) Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J. Hypertens. 24, 1365-1373
106. 1-receptor blockade in the prevention and reversal of atherosclerosis. J. Hum. Hypertens. 16 (Suppl. 3), S34-S41
107. Schupp, M., Janke, J., Clasen, R., Unger, T. and Kintscher, U. (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109, 2054-2057
108. Schupp, M., Clemenz, M., Gineste, R. et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54, 3442-3452
109. Yoshida, T., Yamagishi, S., Nakamura, K. et al. (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-γ activation. Diabetologia 49, 3094-3099
110. Scalera, F., Martens-Lobenhoffer, J., Bukowska, A., Lendeckel, U., Tager, M. and Bode-Boger, S. M. (2008) Effect of telmisartan on nitric oxide - asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor γ and peroxisome proliferator activated receptor γ signaling during endothelial aging. Hypertension 51, 696-703
111. Clasen, R., Schupp, M., Foryst-Ludwig, A. et al. (2005) PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46, 137-143
112. Davies, S. S., Pontsler, A. V., Marathe, G. K. et al. (2001) Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists. J. Biol. Chem. 276, 16015-16023
113. 2 and the ligation of PPARγ. J. Clin. Invest. 112, 945-955
114. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83, 813-819
115. Tzameli, I., Fang, H., Ollero, M. et al. (2004) Regulated production of a peroxisome proliferator-activated receptor-γ ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem. 279, 36093-36102
116. Yano, M., Matsumura, T., Senokuchi, T. et al. (2007) Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 100, 1442-1451
117. 2 synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett. 580, 6885-6890
118. Huang, J. T., Welch, J. S., Ricote, M. et al. (1999) Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378-382
119. Liu, Y., Zhu, Y., Rannou, F. et al. (2004) Laminar flow activates peroxisome proliferator-activated receptor-γ in vascular endothelial cells. Circulation 110, 1128-1133
120. Liu, Y., Zhang, Y., Schmelzer, K. et al. (2005) The antiinflammatory effect of laminar flow: the role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U.S.A. 102, 16747-16752
121. 2 synthase expression in vascular endothelial cells. Circ. Res. 86, 967-973
122. Christianson, J. L., Nicoloro, S., Straubhaar, J. and Czech, M. P. (2008) Stearoyl-CoA desaturase 2 is required for peroxisome proliferator-activated receptor γ expression and adipogenesis in cultured 3T3-L1 cells. J. Biol. Chem. 283, 2906-2916
123. Waki, H., Park, K. W., Mitro, N. et al. (2007) The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARγ expression. Cell Metab. 5, 357-370
124. Xu, H. E., Lambert, M. H., Montana, V. G. et al. (1999) Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3, 397-403
125. Schopfer, F. J., Lin, Y., Baker, P. R. et al. (2005) Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand. Proc. Natl. Acad. Sci. U.S.A. 102, 2340-2345
126. Baldus, S., Eiserich, J. P., Brennan, M. L., Jackson, R. M., Alexander, C. B. and Freeman, B. A. (2002) Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radical Biol. Med. 33, 1010
127. Ischiropoulos, H. (2003) Biological selectivity and functional aspects of protein tyrosine nitration. Biochem. Biophys. Res. Commun. 305, 776-783
128. Rubbo, H. and Radi, R. (2008) Protein and lipid nitration: role in redox signaling and injury. Biochim. Biophys. Acta 1780, 1318-1324
129. Radi, R. (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. U.S.A. 101, 4003-4008
130. Shishehbor, M. H., Aviles, R. J., Brennan, M. L. et al. (2003) Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, J. Am. Med. Assoc. 289, 1675-1680
131. Baker, P. R., Lin, Y., Schopfer, F. J. et al. (2005) Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 280, 42464-42475
132. Baker, P. R., Schopfer, F. J., Sweeney, S. and Freeman, B. A. (2004) Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. Proc. Natl. Acad. Sci. U.S.A. 101, 11577-11582
133. Mitschke, A., Gutzki, F. M. and Tsikas, D. (2007) 9- and 10-Nitro-oleic acid do not interfere with the GC-MS quantitative determination of nitrite and nitrate in biological fluids when measured as their pentafluorobenzyl derivatives. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851, 287-291
134. Lima, E. S., Di Mascio, P., Rubbo, H. and Abdalla, D. S. (2002) Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. Biochemistry 41, 10717-10722
135. Balazy, M. and Poff, C. D. (2004) Biological nitration of arachidonic acid. Curr. Vasc. Pharmacol. 2, 81-93
136. Lima, E. S., Di Mascio, P. and Abdalla, D. S. (2003) Cholesteryl nitrolinoleate, a nitrated lipid present in human blood plasma and lipoproteins. J. Lipid Res. 44, 1660-1666
137. Freeman, B. A., Baker, P. R., Schopfer, F. J., Woodcock, S. R., Napolitano, A. and d'Ischia, M. (2008) Nitro-fatty acid formation and signaling. J. Biol. Chem. 283, 15515-15519
138. Alexander, R. L., Bates, D. J., Wright, M. W., King, S. B. and Morrow, C. S. (2006) Modulation of nitrated lipid signaling by multidrug resistance protein 1 (MRP1): glutathione conjugation and MRP1-mediated efflux inhibit nitrolinoleic acid-induced, PPARγ-dependent transcription activation. Biochemistry 45, 7889-7896